Biography

Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 190 papers and is an inventor of over 250 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB; merged with Cartesian Therapeutics NASDAQ: RNAC), Tarveda Therapeutics and PrognomiQ, where he serves as Chair of Board. Omid is a 2023 Mustafa Prize and the 2013 RUSNANOPRIZE for his work on nanomaterial surface modificagtion. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.